News & Views Published: 08 April 2015 Cancer An extravascular route for tumour cells Mary J. C. Hendrix Nature 520, 300–302 (2015) Cite this article ...

研究成果以“血管外周递送IGF1R拮抗剂在啮齿类及猪动物模型中抑制腹主动脉瘤（Extravascular administration of IGF1R antagonists protects against aortic aneurysm in rodent and porcine models）”为题，于2024年5月1日在《科学·转化医学》（Science ...

Voydeya (danicopan tablets) has been approved in Canada as an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have ...

The novel extravascular implantable cardioverter defibrillator was implanted safely and was able to detect and terminate ventricular arrhythmias, according to a premarket study presented at the ...

DUBLIN, Oct. 23, 2023 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, has received U.S. Food and Drug Administration (FDA) approval for the Aurora EV-ICD™ MRI ...

An extravascular implantable cardioverter defibrillator was associated with effective treatment and low complication rates at 12 to 18 months, researchers reported at Heart Rhythm 2023. As Healio ...

The Food and Drug Administration (FDA) has approved Voydeya ™ (danicopan) as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with ...

Meeting Coverage > ESC Extravascular ICD Gains Ground in Unfamiliar Territory — Inappropriate shocks among early challenges of device therapy under the sternum by Nicole Lou, Senior Staff Writer ...

Introduction Régis Peffault de Latour 1, 2, 3 and Antonio M. Risitano 3, 4 1. French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria, Assistance Publique ...

The Medtronic Extravascular Implantable Cardioverter Defibrillator or EV ICD system is designed to treat dangerously fast heart rhythms that can lead to sudden cardiac arrest, while avoiding ...

The FDA approved the oral factor D inhibitor danicopan (Voydeya) as an add-on therapy to treat extravascular hemolysis in adults with paroxysmal nocturnal hemoglobinuria (PNH), AstraZeneca announced.